Objective. Postherpetic neuralgia (PHN) is common in the United States. Current treatment options for PHN are fairly limited. Spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) are considered mostly experimental and still rarely performed in patients with PHN.
Introduction
There are 1 million new cases of acute herpetic zoster (AHZ) per year in the United States [1] , mostly affecting the elderly population [2] . AHZ and neuropathic pain are caused by reactivated Varicella Zoster Virus (VZV) inflammation that leads to demyelination, Wallerian degeneration, and sclerosis deafferentation [3] [4] [5] in the spinal or cranial sensory ganglia and peripheral nerves, inducing abnormal nociceptor sensitization and central hyperexcitability [6] . Neuropathic pain usually resolves within several months after the onset of herpetic rash [7] , but approximately 9% to 14% of patients develop postherpetic neuralgia (PHN) with a persistent or intermittent burning, aching, electric shock, or/and lancinating type of pain [8] . The pain is usually in one or two adjacent dermatomes, most commonly in thoracic, cervical, or ophthalmic dermatomes [7, 9] .
The treatment options for PHN are still considered suboptimal, and they consist of topical analgesics (lidocaine and capsaicin), pharmaceutical management (anticonvulsants, tricyclic antidepressants, opioid analgesics, and N-methyl-D-aspartate receptor antagonists), transcutaneous electrical nerve stimulation (TENS), behavioral therapy, blocks (epidural, intercostal nerve, and stellate ganglion), and steroid injections [10, 11] . Spinal cord stimulation (SCS) and subcutaneous peripheral nerve stimulation (sPNS) are considered last resort treatments for PHN as SCS efficacy is dependent on activation of anatomically intact spinal pathways, with efficacy inversely correlated with the level of deafferentation [9, 12] .
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Methods

Data Collection
Retrospectively, electronic medical records in our center were reviewed from May of 2005 and May of 2015 to assess patient indications, outcomes, and complications. Patients' pain scores were determined preoperatively and postoperatively by a subjective assessment on a numeric rating scale (NRS). When assessing pain scores, the perioperative medical therapy had been taken into account. The study was approved by the Mayo Clinic's Institutional Review Board No. 13-008640.
Literature Search
PubMed, Ovid, and EBMR databases were searched for the key words "spinal cord stimulation" AND "postherpetic neuralgia" for the time period from 1967 to April 15, 2015 . PubMed, Ovid, and EBMR databases were searched for the key words "peripheral nerve stimulation" AND "postherpetic neuralgia," "percutaneous field stimulation," AND "postherpetic neuralgia" for the time period from 1967 to May 18, 2015.
Selection of Reports
Abstracts were further manually examined for relevance. Articles that were excluded were review articles, had nonhuman subjects, and or focused on PNS of cranial nerves.
Results
Literature Review for SCS
There were 75 reports in OVID/EBMR databases and 32 reports in a PubMed search that had "spinal cord stimulator" and "postherpetic neuralgia" key words. After manually examining abstracts, there were 20 original reports with SCS performed on PHN patients. of these 20, 16 reports had a permanent implantation of SCS and four reports used a temporary type of SCS [13] [14] [15] [16] (Table 1 ).
The 16 reports with permanent SCS included 255 patients, of whom 120 patients received long-term relief (47.1%) (Table 1A ). In these 16 reports, detailed pain scores were available in 11 reports with a total of 66 patients, and the average pain relief was 79.0% (Table  1A) . Moreover, in 12 of 16 reports, implantation was preceded with SCS trial while four reports did not discuss if an SCS trial was used. The follow-up data were available in 12 reports, and the average follow-up was 50.8 months. The discussion on the usage of medication after the SCS, as well as the precise location of the SCS implantation, was quite limited (Table 1A) .
For reports that used temporary trial SCS, 42 out of 54 patients received long-term relief (77.8%). Temporary SCS was performed within six months after the symptoms of active HZ were resolved. The average follow-up was 3.2 months, with average pain relief of 57.0% (Table 1B) .
Literature Review for PNS
One hundred three reports in OVID/EBMR databases and 46 reports in PubMed had "peripheral nerve stimulation" and "postherpetic neuralgia" key words. After manually examining abstracts, six original reports had subcutaneous sPNS performed in PHN patients in the thoracic area. Overall 19 patients were enrolled in those six reports ( Table 2 ).
The largest study on sPNS had 12 PHN patients [36] ; however, patients were not separated by the type of the neuropathic pain, and consequently we could not draw a conclusion on the success rate of the PHN patients ( Table 2 ).
Another study also had a mixed patent population [26] , where either SCS or sPNS was implanted; it was not clear if the two PHN patients in the study had SCS of the sPNS implanted (Table 2) .
Patients who received sPNS on average suffered from PHN for 3.3 years; the average long-term relief was 90.0%, and the average follow-up was 3.8 months. After inclusion of our two cases, the average period of pain due to PHN was 4.1 years, pain relief from sPNS was 88.3%, and the average follow-up was 9.5 months ( Table 2) .
sPNS Cases in MCF
Patient 1
A 57-year-old male had a two-year history of PHN in the left fifth thoracic nerve distribution. The patient was originally treated with antiviral medication, and the rash subsequently resolved. The patient, however, continued to have ongoing burning pain and significant allodynia in the distribution of his prior rash. The pain was sharp, burning, and electrical, with an average daily pain score of 9 out of 10 on an NRS preoperatively. The patient's pain had not responded to gabapentin, baclofen, nortriptyline, oxycodone, or compounded cream of amitriptyline, gabapentin, and lidocaine. In addition to pharmacotherapy, he had two intercostal nerve blocks, TENS unit therapy, and a thoracic intralaminar epidural steroid injection, with no relief of his pain. The patient was taking pregabalin 75 mg twice daily, baclofen 10 mg daily, topical diclofenac, fentanyl patch 50 mcg/h, and also oxycodone/acetaminophen 10/325 eight tablets daily with minimal relief (morphine milligram equivalent (MME) of 120 mg/d). Pregabalin led to some sedation even at 100 mg per day. The patient also failed therapy with duloxetine, which caused sedation and GI upset. *The data were part of a large study, and data were not specifically separated for PHN.
The patient had multiple myeloma that was stable at the time and chronic renal insufficiency.
We decided to try combined trials of sPNS and SCS, where the patient responded positively to both, with more than 75% pain relief.
Due to the patient's copious bleeding during the attempt of a placement of paddles for the SCS, we opted to implant sPNS only. Two octapolar Advanced Scientific leads were implanted 5 cm and 8 cm to the left of midline in the midthoracic area in a parasagittal plane, immediately subcutaneous to his pain area. The Swift-Lock anchors were attached and sewn to the subcutaneous fascia with silk ties. The battery was placed in a pocket in the left upper buttock. The patient had a history of multiple myeloma, but there was no new neoplasia that could have caused the engorged epidural and paraspinal veins that were the source of copious bleeding during the attempt at placing the paddles for the SCS.
The patient has had significant improvement in his ongoing burning pain with sPNS. He had paresthesia from the stimulator that covered his area of pain. The patient was gradually tapered from his medications; at two-month follow-up, his pain medications had decreased to 10 mg of oxycodone three times per day (MME 45 mg/day), equal to the level at 10 months' follow-up. The patient reported good pain control at the level of the patient's postherpetic neuralgia at three, five, eight, and 10 months of follow-up.
The patient had new pain that occurred at 3.5 and six months, which he rated between 0 and 5 out of 10 on an NRS. This new pain was outside the area of the stimulator leads, which was confirmed with fluoroscopy.
Unfortunately, the patient died 11 months after the procedure due to a heart attack and pulmonary embolism unrelated to PHN or sPNS.
Patient 2
A 62-year-old male had an eight-year history of PHN after developing a vesicular rash in the right 5th thoracic nerve distribution, which was refractory to dorsal column stimulator therapy. The patient had SCS already implanted four years prior, which did improve a significant portion of his pain located on his right upper back. Unfortunately, he continued to have pain located largely in the right axillary region. This pain was stabbing and shock-like. The patient was originally treated with acyclovir 800 mg five times a day for 10 days, but the substantial pain never subsided. He reported an average daily pain score of 9 out of 10 on an NRS preoperatively, which at first responded to amitriptyline 50 mg, gabapentin, and lidocaine patches, but then became refractory to these treatments. The patient also tried OxyContin 20 mg three times a day, pregabalin 150 mg in the morning and 75 mg in the evening, compounded cream, steroid injections, and a dorsal column stimulator.
The decision to proceed with permanent implantation sPNS was made after he had undergone a trial that achieved more than 50% pain relief. Two puncture sites were chosen just medial to the patient's area of pain; two St. Jude Medical octopolar leads were implanted in the right chest wall in a parasagittal plane over the region of his pain. The Swift-Lock anchors were attached to the electrode and secured with silk ties to the chest wall fascia. IPG was placed in the subcutaneous pocket in the right lateral abdomen.
The patient was seen one week, one month, six months, two years, and 2.5 years after the procedure. At 2.5 years of follow-up, he reported only occasional breakthrough pain rated 6 out of 10 on an NRS at worst; the patient was not on opioid pain medications. The patient's pain reduction was 80%. *The data was part of a large study and data was not specifically separated for PHN patients. † The data from the current case report.
Discussion
Postherpetic neuralgia is a relatively common, chronic, and debilitating condition, afflicting 1% to 3% percent of the population [1, 38] . Currently, treatments seen as effective for PHN are tricyclic antidepressants, gabapentin, pregabalin, opioids, and topical lidocaine patches [39] . From randomized, double-blind studies, 32% to 34% of patients treated with gabapentin had 50% or greater pain relief [40] , 50% of patients treated with pregabalin had 50% or greater pain relief [41] , 47% to 67% of patients treated with antidepressants had 50% or greater pain relief [42] , and 31% of patients treated with lidocaine patch had 50% or greater pain relief [43] . Patients treated with opioids had A mean pain relief of 38% [44] .
SCS is rarely offered to patients with PHN. Long-term pain relief from a permanent type of SCS was achieved in 47.1% of the reported PHN patients (Table 1A) (Table 1B) . More patients received long-term pain relief from a temporary SCS; however, the duration of long-term pain relief was substantially shorter in temporary SCS studies. In temporary SCS treatment reports [13] [14] [15] [16] , patients were followed after the treatment had ended, which is different from permanent-type SCS where patients were still on treatment in their followups. Patients with temporary SCS [13] [14] [15] [16] received treatment much sooner after the symptoms of active HZ were resolved, compared with trails of permanent-type SCS, which might contribute to patients not developing chronic sensitization, resulting in better outcomes.
The longest follow-up in the literature for sPNS was six months, which is much shorter than reported follow-ups for SCS in PHN. Our follow-ups were 10 months and 2.5 years, offering some insight into the durability of sPNS as a treatment for PHN. The average pain relief was 90% (88.3% when the patients from our practice are included). sPNS is a promising method that is still developing. From our own limited experience and literature reports, it seems that sPNS might prove to be an effective option for patients who have already tried SCS or for patients who are not good candidates for SCS.
The main limitation of this study is its small sample size, where we were not able to evaluate the full potential of sPNS in PHN patients. However, this is also a limitation of the whole field.
It would be beneficial to the neurostimulation field and patients in the long run if a multisite clinical trial and registry of current sPNS cases were established in order to standardize techniques and collect outcome data. We would be interested in participating and supporting this research.
